理财周报见习记者 钱文俊/文

Finance QianWenJun/the apprentice weekly newspaper reporters

　　光大证券(601788,股吧)抛10亿定增预案引暴跌，孙婷“增持” Everbright securities(601788,Shares it)The plan will throw 1 billion led slump，SunTing“increasing”

　　光大证券8月1日公布不超过6亿股的A股定向增发方案，拟定向增发募资70亿元用于补充资本金，其第二大股东光大控股将参与认购。当天光大证券放量大跌5.50%。

Everbright securities announced on August 1, no more than 600 million shares A shares by directional plan，To develop secondary whip round 7 billion yuan used to add capital，The second largest shareholder everbright holding will participate in subscribe。Everbright securities plunged tumbled 5.50% on the day。

　　孙婷认为，定增完成后，公司净资本和净资产将扩增至200.51亿、284.17亿。募集资金将有效补充公司营运资金，扩大创新业务规模，提升公司的市场竞争力和抗风险能力。

SunTing think，Set after the completion of the increase，The company net capital and net assets will enlarge increased to 20.051 billion、28.417 billion。Raising money will be effective supplement company operating funds，Expand the scale of business innovation，Promotes the company's market competitiveness and anti-risk ability。

　　公司业务结构均衡，综合实力处于行业领先水平，将受益于行业转型改革。2012-2013年EPS为0.55元和0.63元。

The company business structure equilibrium，Comprehensive strength in an industry leading level，Will benefit from the industry transition reform。2012-2013 EPS to 0.55 yuan and 0.63 yuan。

　　东方证券江维娜“增持”北陆药业 JiangWeiNa Orient securities“increasing”BeiLiu pharmaceutical

　　江维娜7月31日发布《营销改革见效，业绩有突破》报告，认为，公司在两年时间内迅速剥离了利润率低、消耗资金的医药营销业务，聚焦主业，预期未来能够全面扩大其竞争优势，在行业整体向好的环境中，取得高速的增长。预测公司2012-2014年EPS分别为0.39元、0.51元和0.64元，使用相对估值法取A股可比上市公司2012年调整平均35倍PE估值水平，对应目标价13.65元。

JiangWeiNa released on July 31《Marketing reform effective，Performance a breakthrough》report，think，The company in two years time quickly stripped of low profit margins、Consumption of capital medicine marketing business，Focus on its main business，The expected future can fully expanding its competitive advantage，In the whole industry to the good environment，Get high-speed growth。The company's 2012-2014 forecast EPS 0.39 yuan respectively、0.51 yuan and 0.64 yuan，Use relative valuations law take A shares listed company than 2012 average adjustment 35 times PE valuation levels，Corresponding target price of 13.65 yuan。

　　评价参照：上周仅有该份报告。

Evaluation with reference to：Only last week the report。

　　日信证券赵越“推荐”青青稞酒 Faith, ZhaoYue securities“recommend”Green of barley wine

　　最新价27.79元 The latest price of 27.79 yuan

　　赵越7月30日发布《快速增长在预期之内》，认为2012年一季报中曾预计上半年净利润同比增长30%-50%，而上半年市场扩张按部就班进行，中期营业利润同比增长42.02%、净利润同比增长43.34%的成绩在市场预期之列。预计公司2012-2014年的业绩分别为0.645元、0.849元、1.101元，目前股价对应估值分别为41.91倍、31.85倍和24.56倍。

ZhaoYue released on July 30《Rapid growth in within the expected》，Believe that 2012 years a quarterly net profit in the first half year-on-year growth had been expected to 30%-50%，In the first half step by step and market expansion，Mid-term operating profit up 42.02%、Net profit up 43.34% performance on the market is expected to list。The company is expected to 2012-2014 performance of 0.645 yuan respectively、0.849 yuan、1.101 yuan，Current share prices were 41.91 times the corresponding valuations、31.85 times and 24.56 times。

　　评价参照：上周公布2份研报。其中民生王永峰维持“强烈推荐”评级。

Evaluation with reference to：2 a research report published last week。Among them WangYongFeng maintain the people's livelihood“Strongly recommend”rating。

　

　招商李姗姗“推荐”博雅生物 Investment promotion li shanshan“recommend”Boya biological

　　最新价30.16元 The latest price of 30.16 yuan

　　目标价：30.59元 Target price：30.59 yuan

　　李姗姗7月30日发布《批签发量提升，预计下半年净利增速加快》，她认为，博雅生物(300294,股吧)作为区域性龙头血制品企业，规模小，弹性大，2011年库存产品充足，乙肝特免已获批签发，未来岳池、灌云浆站将大幅提高公司采浆能力，同时有新浆站获批可能。

Li shanshan released on July 30《Batch quantity issued ascension，Second half net profit growth is expected to accelerate》，She thought，Boya biological(300294,Shares it)As a regional leading blood product enterprise，Small scale，flexibility，2011 stock product enough，Second liver, has approved from issuing，Future YueChi、Filling slurry will greatly improve cloud stood in the pulp ability，At the same time there is a new plasma stand approved may。

　　预计2012~2014年EPS为0.99、1.13、1.31元，对应PE分别为31、27、23倍，首次给予“审慎推荐-A”投资评级。

2012 ~ 2014 year EPS is expected to 0.99、1.13、1.31 yuan，Corresponding PE for 31 respectively、27、23 times，First give“Prudent recommend-A”Investment rating。

　　评价参照：上周共有2份研报。其中湘财证券李晓彬维持“增持”评级。

Evaluation with reference to：Last week there were 2 copies of research report。Among them XiangCai securities LiXiaoBin maintain“increasing”rating。

　

　中银国际王军“买入”上海凯宝 Boc international royal army“buy”Shanghai KaiBao

　　最新价25.71元 The latest price of 25.71 yuan

　　目标价：32元 Target price：32 yuan

　　王军7月31日发布《继续保持高速增长》，认为公司在清热解毒类中药注射剂市场占有率居前，在中药注射剂领域具有一定的技术优势。痰热清注射液疗效确切、不良反应率低，随着募投项目投产解除了产能瓶颈。预计公司2012-2014年每股收益分别为0.922元、1.244元、1.687 元，首次给予买入的评级，目标价格32.00元。

The royal army released on July 31《Continue to maintain high growth》，Think the company in qingrejiedu kind of tcmi in market share before，In tcmi field has some of the technological advantages。Phlegmy heat qing injection curative effect is accurate、Adverse reaction rate is low，As for offering project put into production, lifted the capacity bottlenecks。The company is expected to 2012-2014 earnings per share were 0.922 yuan、1.244 yuan、1.687 yuan，To buy rating for the first time，Target price of 32.00 yuan。

　　评价参照：上周公布5份报告。其中西南证券(600369,股吧)梁从勇“增持”上海凯宝(300039,股吧)。

Evaluation with reference to：5 report released last week。Southwest of securities(600369,Shares it)Beam from yong“increasing”Shanghai KaiBao(300039,Shares it)。

　

　瑞银证券王鹏“买入”酒鬼酒 Ubs securities WangPeng“buy”Drunkard wine

　　最新价50.06元 目标价：72.2元 The latest price $50.06 price target：72.2 yuan

　　王鹏7月31日发布《恢复对公司的覆盖，上调评级至“买入”》，认为公司业绩大幅增长主要来自高档酒销售收入大幅增加，以及费用率的降低。公司自2011年第二季度以来，已经实现了连续5个季度的收入环比增长，我们认为增长的质量是比较高的。恢复对公司的覆盖，预计2012-2014年公司收入18.14/25.85/33.65亿元，EPS为1.41/2.20/3.02元（原0.91/1.36/1.83元）。

WangPeng released on July 31《Restore on company's coverage，Raised rating to“buy”》，Think the company performance greatly growth came mainly from high-grade wine sales income increase，And the lower rate。Since 2011 the company since the second quarter，Has been realized for five consecutive quarters of income annulus comparing growth，We think that quality is the growth of relatively high。Restore on company's coverage，2012-2014 is expected to company income 3.365 billion yuan / 18.14/25.85，EPS to 1.41/2.20/3.02 yuan（The original 0.91/1.36/1.83 yuan）。

　　评价参照：上周公布16份研报。其中申银万国童驯维持“买入”评级。

Evaluation with reference to：16 a research report published last week。Among them ShenYin WanGuoTong training to maintain“buy”rating。

　

　东兴弓永峰“强烈推荐”格林美 GongYongFeng following“Strongly recommend”Green beauty

　　最新价13.42元 The latest price of 13.42 yuan

　　弓永峰8月3日发布《收购凯力克，上游下游齐拓展》报告，认为收购凯力克后，公司在上下游选择上具有更高的灵活度，能够根据市场情况对上游原材料和下游产品进行调整，有效地规避金属钴价格波动对公司业绩的影响。预测凯力克对公司业绩贡献的情况下，预计公司2012年-2014年EPS分别为0.33元、0.49元，对应PE40.33倍、27.16倍，上调公司评级至强烈推荐。

On August 3, GongYongFeng release《Acquisition kay's，The upstream downstream expand together》report，Think acquisition kay after assertions，The company in the upstream and downstream choice has higher flexibility，According to the market situation can for upstream and downstream products of raw materials adjustment，Effectively evade cobalt metal prices on the influence of the performance of the company。Forecast's contribution to the company performance kay，Expect the company in 2012-2014, EPS 0.33 yuan respectively、0.49 yuan，Corresponding PE40.33 times、27.16 times，Raise the company to strongly recommended rating。

　　评价参照：上周公布4份研报。其中中金蔡宏宇维持“审慎推荐”评级。

Evaluation with reference to：4 a research report published last week。Among them CaiHongYu cicc, maintain“Prudent recommend”rating。

　

　宏源证券(000562,股吧)胡颖“买入”德豪润达 Hongyuan securities(000562,Shares it)HuYing“buy”DE hao embellish of

　　最新价5.83元 The latest price of 5.83 yuan

　　目标价：9元 Target price：$9

　　胡颖8月2日发布《路灯与商照启动，业绩渐现曙光》报告，预计未来3年市场空间超400亿元。

HuYing released on August 2《Street lamps and business according to start，Performance gradually now dawn》report，The expected future three years market space exceeds 40 billion yuan。

　　预计2012-2014年公司复合增长77%。

2012-2014 the company is expected to increase 77% compound。

　　评价参照：上周公布2份研报。兴业证券(601377,股吧)刘亮维持“增持”评级。

Evaluation with reference to：2 a research report published last week。Industrial securities(601377,Shares it)LiuLiang maintain“increasing”rating。

　

　安信证券刘军“增持”金正大 Anxi LiuJun securities“increasing”JinZhengDa

　　最新价14.45元 目标价：17.6元 The latest price $14.45 price target：17.6 yuan

　　刘军7月31日发布《业绩符合预期，硝基复合肥逐步发力》，认为硝基复合肥是公司目前主推品种，用于瓜果蔬菜等经济作物，毛利可达25%。预测2012年每股收益0.88元，按20倍PE估值，6个月目标价为17.6元。

LiuJun released on July 31《Results in line with expectations，The nitro compound fertilizer send force gradually》，Think the nitro compound fertilizer is the company at present main varieties，Used for lots of fruits and vegetables and economic crops，Maori can amount to 25%。Forecast 2012 earnings per share of 0.88 yuan，According to 20 times PE valuations，6 months price target of $17.6。

　　评价参照：上周共有4份研报。申银万国周小波维持“增持”评级。

Evaluation with reference to：There were four a research report last week。ShenYin WanGuoZhou wavelet to maintain“increasing”rating。

　　宏源证券王凤华“买入”壹桥苗业 Hongyuan securities WangFengHua“buy”One bridge MiaoYe

　　最新价40.4元 The latest price of 40.4 yuan

　　目标价：60元 Target price：60 yuan

　　王凤华7月30日发布《等待秋季收获，业绩爆发超预期》报告，认为2012年下半年业绩将出现拐点，2013年开始迎来持续3年的爆发式增长。预测2012-2014年归属于母公司的净利润分别是1.7亿、3.9亿、5.9亿。

WangFengHua released on July 30《Waiting for the autumn harvest，Performance outbreaks than expected》report，Believe that 2012 years second half performance will be a turning point，Beginning in 2013 in the last 3 years BaoFaShi growth。Forecast 2012-2014 net profit attributable to the parent company and the 170 million respectively、390 million、590 million。

　　评价参照：上周共有3份报告。民生证券王莺维持“强烈推荐”，中信毛长青维持“持有”评级。

Evaluation with reference to：There are three reports last week。Stock WangYing maintain the people's livelihood“Strongly recommend”，Citic MaoChangQing maintain“hold”rating。

　

　湘财证券叶侃“买入”尚荣医疗 XiangCai securities YeKan“buy”ShangRong medical

　　最新价21.2元 The latest price of 21.2 yuan

　　目标价：23元 Target price：23

　　叶侃8月1日发布《大订单转化能力得到肯定，业绩高成长趋于明朗》报告，认为合同金额高于先前中标金额和框架性协议的预期投资金额，两个项目将在2014年底或者2015年初确认收入，业绩高成长趋于明朗。预计公司2012-2014年摊薄后EPS分别为0.27元、0.50元和1.18元。

YeKan August 1 issued《Big order transformation ability get affirmation，High growth performance tend to clear》report，Think the contract value than previously expected amount and framework agreement investment，Two projects will be in the end of 2014 or early 2015 confirmed that income，High growth performance tend to clear。The company is expected to 2012-2014 diluted EPS after 0.27 yuan respectively、0.50 yuan and 1.18 yuan。

　　评价参照：上周公布2份研报。安信证券李孔逸维持“买入”评级。

Evaluation with reference to：2 a research report published last week。Anxi LiKongYi maintain securities“buy”rating。

　　广发证券(000776,股吧)王飞2月6日“买入”北京利尔(002392,股吧)目标价15元，最新价8.61元，低于目标价42.6%。

Wide hair negotiable securities(000776,Shares it)WangFei February 6,“buy”Beijing Lear's(002392,Shares it)Target price of $15，The latest price of 8.61 yuan，Target price lower than 42.6%。

　　安信证券刘军1月3日“买入”金正大(002470,股吧)目标价18.45元，最新价14.45元，低于目标价21.7%。

Anxi securities LiuJun January 3“buy”JinZhengDa(002470,Shares it)Target price of 18.45 yuan，The latest price of 14.45 yuan，Target price lower than 21.7%。

　　华宝证券吴炳华1月11日“买入”世纪瑞尔(300150,股吧)目标价24.75元，最新价15.14元，低于目标价38.8%

Stock WuBingHua huabao bird on January 11“buy”Century's red(300150,Shares it)Target price of 24.75 yuan，The latest price of 15.14 yuan，Target price lower than 38.8%